The aim of the present study was to determine whether cleavage of the Her-2/neu ECD is correlated with overall tyrosine kinase activity in vivo and might therefore constitute a clinically relevant ligand-independent mechanism for the activation of Her-2/neu in breast cancer. Here, ERBB2 is linked to breast cancer.